GlaxoSmithKline Plc CEO Andrew Witty tells reporters: * CEO says any ViiV IPO likely to be 2016 event * CEO says globally scaled businesses post-Novartis deal will have more options * CEO says not giving any guidance for 2016 dividend * CEO says share of new respiratory patients in Japan, U.S. has started to go up in recent weeks * CEO says 29 percent in 2014 smoking cessation product sales mainly due to supply problems, rather than e-cigarette competition * CEO says believes has potential to compete in next-generation mmuno-oncology,
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. Shares of GSK traded higher by 0.68% or $0.3/share to $44.26. In the past year, the shares have traded as low as $41.25 and as high as $56.73. On average, 3866760 shares of GSK exchange hands on a given day and today's volume is recorded at 5180564.
Source
